![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
KJ Schuh, SL Walsh, GE Bigelow, KL Preston and ML Stitzer
Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
One purpose of this study was to characterize the acute effects of the partial mu-opioid agonist buprenorphine administered to human subjects undergoing maintenance treatment with ascending doses of morphine. A second purpose was to examine the development of tolerance, cross- tolerance and physical dependence under the same morphine maintenance conditions. Six opioid-dependent volunteers were treated chronically with ascending morphine doses of 15, 30, 60 and 120 mg/day. Each morphine dosing level was maintained for 2 weeks, with test drugs administered during the second week of maintenance of each morphine dose. Both morphine (30 mg i.m.) and buprenorphine (6 mg i.m.) constricted pupils and produced reports of opioid-like subjective effects. The magnitude of these effects was inversely related to the morphine maintenance dose, with no effects being detected at higher maintenance levels. Naloxone (0.3 mg) produced little effect at lower morphine maintenance doses but precipitated withdrawal at higher maintenance doses. Buprenorphine failed to precipitate withdrawal even when subjects were treated with 120 mg/day morphine. These findings indicate that dose-dependent tolerance to morphine, cross-tolerance to buprenorphine and physical dependence develop during morphine maintenance. The finding that buprenorphine does not act as an antagonist under these dosing conditions further supports the clinical observation that there are conditions under which patients dependent on short-acting opioids can be comfortably transferred directly to buprenorphine maintenance treatment.
This article has been cited by other articles:
|
|
 |
|
  T. H. Kelly, W. W. Stoops, A. S. Perry, M. A. Prendergast, and C. R. Rush Clinical Neuropharmacology of Drugs of Abuse: A Comparison of Drug-Discrimination and Subject-Report Measures Behav Cogn Neurosci Rev, December 1, 2003; 2(4): 227 - 260. [Abstract] [PDF]
|
|
|
|
 |
|
 R. M. Allen and L. A. Dykstra N-Methyl-D-Aspartate Receptor Antagonists Potentiate the Antinociceptive Effects of Morphine in Squirrel Monkeys J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 288 - 297. [Abstract] [Full Text]
|
|
|
|
|
|
R. M. Allen and L. A. Dykstra Attenuation of {micro}-Opioid Tolerance and Cross-Tolerance by the Competitive N-Methyl-D-aspartate Receptor Antagonist LY235959 Is Related to Tolerance and Cross-Tolerance Magnitude J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1012 - 1021. [Abstract] [Full Text]
|
|
|
|
|
|
T. Eissenberg, M. L. Stitzer, G. E. Bigelow, A. R. Buchhalter, and S. L. Walsh Relative Potency of levo-alpha -Acetylmethadol and Methadone in Humans under Acute Dosing Conditions J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 936 - 945. [Abstract] [Full Text]
|
|
|
|
|
|
E. J. Houtsmuller, S. L. Walsh, K. J. Schuh, R. E. Johnson, M. L. Stitzer, and G. E. Bigelow Dose-Response Analysis of Opioid Cross-Tolerance and Withdrawal Suppression During LAAM Maintenance J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 387 - 396. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
